Prota Therapeutics
Melbourne, Australia· Est.
Australian‑stage biotech delivering oral immunotherapy for peanut allergy with a Phase‑3 ready candidate.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $31M
AI Company Overview
Australian‑stage biotech delivering oral immunotherapy for peanut allergy with a Phase‑3 ready candidate.
Immunology
Technology Platform
Proprietary oral immunotherapy using engineered allergen peptides to induce durable immune tolerance while minimizing anaphylaxis risk.
Opportunities
Large unmet need for disease‑modifying peanut allergy therapy and potential to expand the platform to other major food allergens.
Risk Factors
Clinical trial outcomes, regulatory approval uncertainty, and competition from other oral immunotherapy developers.
Competitive Landscape
Competes with companies such as Aimmune (AR101) and DBV Technologies (Viaskin), but differentiates through a peptide‑engineered OIT platform and a Phase‑3 ready candidate.